FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMerck & Co., Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MRK
Merck & Co., Inc. Stock AnalysisComprehensive stock analysis for Merck & Co., Inc. (MRK) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMRK
MRK
Merck & Co., Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MRK
  1. Home
  2. Stocks
  3. Merck & Co., Inc.

Merck & Co., Inc.

🇺🇸MRK•NYSE

Merck & Co., Inc.

🇺🇸MRK•NYSE
Market cap
$356.13B
Sentiment

Your view on MRK

Mkt Cap
$356.13B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Merck & Co., Inc.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Robert M. Davis
Headquarters
2000 Galloping Hill Road, Rahway, NJ, US
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Robert M. Davis
Headquarters
2000 Galloping Hill Road, Rahway, NJ, US
Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.

The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.

The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Merck & Co., Inc. from FRC's valuation model, read against the market price. MRK last traded at $144.46, 147.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Merck & Co., Inc.. Starting points for Merck & Co., Inc.: P/E 147.4, EPS $0.99, beta 0.22 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Merck & Co., Inc.. Merck & Co., Inc. paid $3.40 per share over the last year — a 2.4% yield at the current $144.46 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Merck & Co., Inc.. Trailing twelve-month EPS for Merck & Co., Inc. stands at $0.99. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$159.00

average of 21 firms, last 12 months

 

$159.00

Low $105.00

Median $165.00

High $180.00

 

Analyst Ratings

Buy21 firms, last 12 months
  • Strong Buy0
  • Buy15
  • Hold6
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.75$2.13$2.79$8.90
Low estimate$1.69$2.09$2.51$8.44
High estimate$1.87$2.17$3.00$9.36
No. of analysts1251414
Year-ago EPS$2.04-$1.28$7.28—
Growth-14.4%+266.3%-61.7%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$16.29B$16.46B$67.25B$69.42B
Low estimate$16.06B$16.23B$66.97B$68.71B
High estimate$16.49B$16.72B$67.65B$70.16B
No. of analysts1041818
Year-ago revenue$16.32B$16.29B$64.93B—
Growth-0.2%+1.1%+3.6%—
Recent analyst actions15 rating and price-target changes, latest Nov 2, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, MarketWatch; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Merck & Co., Inc.. Merck & Co., Inc. has reported as a listed company since 1978. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MRK18 companies · 8 funds
Compare MRK with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABBVAbbVie Inc.Drug Manufacturers - General$520.9B
  • AMGNAmgen Inc.Drug Manufacturers - General$250.1B
  • AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
  • GILDGilead Sciences, Inc.Drug Manufacturers - General$207.9B
  • JNJJohnson & JohnsonDrug Manufacturers - General$687.9B
  • LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
  • NVSNovartis AGDrug Manufacturers - General$302.6B
  • PFEPfizer Inc.Drug Manufacturers - General$164.5B

More Drug Manufacturers - General companies

  • ALPMYAstellas Pharma Inc.OTC$29.2B
  • AMRNAmarin Corporation plcNASDAQ$234M
  • BAYRYBayer AGOTC$49.0B
  • BIIBBiogen Inc.NASDAQ$37.2B
  • BMYBristol-Myers Squibb CompanyNYSE$128.6B
  • CHGCFChugai Pharmaceutical Co., Ltd.OTC$105.3B
  • CHGCYChugai Pharmaceutical Co., Ltd.OTC$110.0B
  • CHJTFCSPC Pharmaceutical Group LimitedOTC$15.8B
  • CSPCYCSPC Pharmaceutical Group LimitedOTC$14.6B
  • DSKYFDaiichi Sankyo Company, LimitedOTC$34.1B

ETFs holding Merck & Co., Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.56%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.51%
  • IVViShares Core SP 500 ETF$852.9B in assets0.56%
  • SCHDSchwab U.S. Dividend Equity ETF$119.9B in assets3.73%
  • PPHVanEck Pharmaceutical ETF$1.1B in assets11.97%
  • IYHiShares US Healthcare ETF$4.7B in assets5.17%
  • VHTVanguard Health Care ETF$19.1B in assets4.77%
  • FHLCFIDELITY MSCI HEALTH CARE INDEX ETF$4.0B in assets4.58%

Largest holders first, then the funds most concentrated in MRK.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Merck & Co., Inc., and how their positions are changing. At a $356.13B market value, institutional positions materially move Merck & Co., Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Merck & Co., Inc. executives and directors. Shares of Merck & Co., Inc. have traded between $73.31 and $105.07 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Merck & Co., Inc.. Merck & Co., Inc. is a $356.13B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Merck & Co., Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Merck & Co., Inc.. Coverage tracks Merck & Co., Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Merck & Co., Inc.

MRK Analysis
Good
Past5
Growth3
Health3
Profit3
Value1

News

Latest Market News